Strona główna

  • Banner

  • Reduced price
Therapeutic Targeting of RAS Mutant Cancers

Therapeutic Targeting of RAS Mutant Cancers

9781009073646
102,06 zł
91,85 zł Save 10,21 zł Tax included
Lowest price within 30 days before promotion: 91,85 zł
Quantity
Available in 4-6 weeks

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DHL, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Description
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Product Details
Cambridge University Press
97901
9781009073646
9781009073646

Data sheet

Rok wydania
2022
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
38
Wymiary (mm)
152.00 x 228.00
Waga (g)
80
  • Introduction; RAS Biology; Oncogenic RAS; RAS Targeting; Downstream Targeting; Upstream Targeting; Targeting Specific RAS Mutants; KRAS G12C Targeting; Direct Targeting of Other RAS Proteins; KRAS G12R Pancreatic Cancer; KRAS G13D Colorectal Cancer; Summary; References.
Comments (0)
Viewed products

  • Frequently purchased together

    No products available